Vera Therapeutics (VERA) Price & Analysis

Compare

758 Followers

VERA Stock Chart & Stats

$45.11

-$0.18(-0.43%)

At close: Jan 08 4:00 PM EST

$45.11

-$0.18(-0.43%)

Day’s Range― - ―

52-Week Range$18.53 - $56.05

Previous CloseN/A

Volume142.65K

Average Volume (3M)1.47M

Market Cap

$3.16B

Enterprise Value$3.17B

Total Cash (Recent Filing)$497.39M

Total Debt (Recent Filing)$77.22M

Price to Earnings (P/E)―

Beta1.41

Next Earnings

Mar 19, 2026

EPS Estimate

-1.28

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.26

Shares Outstanding70,066,180

10 Day Avg. Volume1,120,971

30 Day Avg. Volume1,474,393

Financial Highlights & Ratios

PEG Ratio-0.69

Price to Book (P/B)4.05

Price to Sales (P/S)0.00

P/FCF Ratio-17.25

Enterprise Value/Market Cap1.00

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-2.81K

Enterprise Value/Ebitda-13.05

Forecast

1Y Price Target

$72.09

Price Target Upside59.81% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering12

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyPhase III ORIGIN results showed substantial reductions in proteinuria across prespecified patient subgroups and no neutralizing anti‑drug antibodies, strengthening atacicept's clinical profile versus competitors.

Commercial Potential And Pricing PrecedentAnalyst highlights that recent competitor pricing and favorable label language for the class could enable premium pricing and a broader eligible patient population, supporting materially higher peak sales projections and higher analyst price targets.

Regulatory ProgressAnalyst notes FDA acceptance of the atacicept biologics license application with Priority Review, supporting a potential commercial launch.

Bears Say

Financial PositionAnalyst highlights high cash burn and a limited cash runway, creating potential funding risk and dependence on capital markets.

Immunogenicity ConcernsA high rate of anti‑drug antibodies reported with a class peer raises concerns about immunogenicity that could affect long‑term efficacy perceptions and complicate competitive positioning.

Market SentimentNotably elevated short interest, around 20% of the float, signals pronounced investor skepticism that could exert downward pressure on the stock.

Vera Therapeutics News

Vera Therapeutics appoints Skelton as Chief Commercial Officer

Vera Therapeutics (VERA) announced the appointment of Matt Skelton to Chief Commercial Officer, effective immediately. Skelton joined Vera...

2d ago

VERA

Vera Therapeutics announces atacicept BLA accepted for Priority Review by FDA

Vera Therapeutics (VERA) announced the atacicept Biologics License Application, BLA, for the treatment of adults with immunoglobulin A...

23d ago

VERA

Wolfe upgrades Vertex Pharmaceuticals, says ‘may be due for a rebound’

As previously reported, Wolfe Research analyst Andy Chen upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Peer Perform with...

24d ago

VERA

VRTX

Buy Rating on Vera: De-Risked Atacicept Approval Path and Large IgA Nephropathy Market Drive Compelling Upside into 2026 Catalysts

In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Vera Therapeutics, with...

23d ago

VERA

Short Report: Vera Therapeutics bears retreat as stock rallies

Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest...

1M ago

MBLY

MDGL

Vera Therapeutics price target raised to $66 from $48 at BofA

BofA raised the firm’s price target on Vera Therapeutics (VERA) to $66 from $48 and keeps a Buy...

1M ago

VERA

Vera Therapeutics price target raised to $95 from $55 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Vera Therapeutics (VERA) to $95 from $55 and keeps a...

1M ago

VERA

Vera Therapeutics price target lowered to $96 from $99 at JPMorgan

JPMorgan lowered the firm’s price target on Vera Therapeutics (VERA) to $96 from $99 and keeps an Overweight...

1M ago

VERA

Vera Therapeutics: Reinforced Buy on Atacicept’s Leading IgAN Profile, Robust Cash Runway, and Expanded Peak Sales Potential

In a report released today, Dina Ramadane from Bank of America Securities reiterated a Buy rating on Vera...

1M ago

VERA

Vera Therapeutics Announces Departure of Chief Legal Officer

An update from Vera Therapeutics ( ($VERA) ) is now available. On December 16, 2025, Vera Therapeutics, Inc....

1M ago

VERA

Vera Therapeutics director buys $250K in common stock

In a regulatory filing, Vera Therapeutics (VERA) disclosed that its Patrick Enright bought 5.9K shares of common stock...

2M ago

VERA

Vera Therapeutics price target raised to $33 from $23 at Wedbush

Wedbush analyst Laura Chico raised the firm’s price target on Vera Therapeutics (VERA) to $33 from $23 and...

2M ago

VERA

Vera Therapeutics Completes Successful Stock Offering

Vera Therapeutics ( ($VERA) ) has shared an announcement. On December 9, 2025, Vera Therapeutics, Inc. announced a...

2M ago

VERA

Vera Therapeutics 6.14M share Secondary priced at $42.50

The deal size was increased to $261M from $200M and priced below last closing price of $44.66. JPMorgan,...

2M ago

VERA

VERA FAQ

What was Vera Therapeutics’s price range in the past 12 months?

Vera Therapeutics lowest stock price was $18.53 and its highest was $56.05 in the past 12 months.

What is Vera Therapeutics’s market cap?

Vera Therapeutics’s market cap is $3.16B.

When is Vera Therapeutics’s upcoming earnings report date?

Vera Therapeutics’s upcoming earnings report date is Mar 19, 2026 which is in 48 days.

How were Vera Therapeutics’s earnings last quarter?

Vera Therapeutics released its earnings results on Nov 05, 2025. The company reported -$1.26 earnings per share for the quarter, missing the consensus estimate of -$1.162 by -$0.098.

Is Vera Therapeutics overvalued?

According to Wall Street analysts Vera Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Vera Therapeutics pay dividends?

Vera Therapeutics does not currently pay dividends.

What is Vera Therapeutics’s EPS estimate?

Vera Therapeutics’s EPS estimate is -1.28.

How many shares outstanding does Vera Therapeutics have?

Vera Therapeutics has 70,066,180 shares outstanding.

What happened to Vera Therapeutics’s price movement after its last earnings report?

Vera Therapeutics reported an EPS of -$1.26 in its last earnings report, missing expectations of -$1.162. Following the earnings report the stock price went down -1.027%.

Which hedge fund is a major shareholder of Vera Therapeutics?

Currently, no hedge funds are holding shares in VERA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Vera Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-73.25%

Trailing 12-Months

Asset Growth

45.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Vera Therapeutics

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Vera Therapeutics (VERA) Earnings & Revenues

Historic Earnings Reports

VERA Stock 12 Month Forecast

Average Price Target

$72.09

▲(59.81% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"$19","60":"$60","101":"$101","39.5":"$39.5","80.5":"$80.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":72.0909090909091,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$72.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$33.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,39.5,60,80.5,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.64,54.43692307692308,58.23384615384615,62.03076923076923,65.8276923076923,69.62461538461538,73.42153846153846,77.21846153846154,81.01538461538462,84.81230769230768,88.60923076923078,92.40615384615384,96.20307692307692,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.64,52.29006993006993,53.94013986013986,55.59020979020979,57.24027972027972,58.89034965034965,60.54041958041958,62.19048951048951,63.840559440559446,65.49062937062938,67.14069930069931,68.79076923076923,70.44083916083916,{"y":72.0909090909091,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.64,49.283076923076926,47.926153846153845,46.56923076923077,45.21230769230769,43.855384615384615,42.49846153846154,41.14153846153846,39.784615384615385,38.42769230769231,37.07076923076923,35.713846153846156,34.35692307692308,{"y":33,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":42.29,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.28,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.93,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.75,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.74,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.61,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.79,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.46,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.64,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >